Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

450 Brookline Avenue, Boston, MA, 02215

Year Opened: 1947
Patients: 12,000 new cancer patients per year
Fast Fact: Dana-Farber ranked fourth in U.S News and World Report's list of top 10 cancer centers in the U.S. for 2015-16.

Doctors in this Hospital

Pasi A. Janne
Thoracic Oncology view more
Bruce Johnson
Medical Oncology view more

About Dana-Farber Cancer Institute

Located in Boston, the Dana-Farber Cancer Institute is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), a consortium that combines the research efforts of seven Harvard-affiliated medical institutions. It’s also the largest National Cancer Institute-designated Comprehensive Cancer Center in the country. The DF/HCC receives more than $500 million per year in research grants sponsored by the National Institutes of Health (NIH). This funding is used to help scientists develop new treatments and therapies to continually improve the outlook for cancer patients.

In addition, Dana-Farber collaborates with Brigham and Women’s Hospital, another leading facility associated with Harvard. According to U.S. News and World Report, Dana-Farber Cancer Institute/Brigham and Women’s Cancer Center ranked fourth on the publication’s list of top 10 U.S. cancer centers for 2015-16.

Dana-Farber’s history of excellence in cancer treatment began in 1947, when Dr. Sidney Farber founded the Children’s Cancer Research Foundation. That same year, Farber discovered an innovative new therapy for leukemia, which at the time came with a poor prognosis and had no effective treatments. He tested the new therapy on 16 children diagnosed with the cancer, and helped 10 of them achieve temporary remission.

In 1969, the foundation extended its state-of-the-art treatments to cancer patients of all ages. To honor Farber and his compassion for patients, the foundation changed its name to the Sidney Farber Cancer Center in 1974. It became the Dana-Farber Cancer Institute in 1983 to commemorate the Charles A. Dana Foundation and its long-term support for cancer research.

Despite changes to the treatment center’s name and focus over the years, one thing has remained constant: A strong commitment to improving cancer care. Dana-Farber sets itself apart from other leading cancer centers by dedicating an equal amount of effort to scientific research and patient care. Close collaboration in these areas laid the foundation for future progress in treating and preventing cancer at the facility.

Treatment Options

A partnership with Brigham and Women’s Hospital gives patients at Dana-Farber access to the International Mesothelioma Program (IMP), the world’s largest treatment center specializing in mesothelioma care. Located just around the corner from the Dana-Farber Cancer Institute, IMP has more than 20 years of clinical and research experience focused on improving survival and making progress toward a mesothelioma cure.

IMP takes a coordinated team approach to treatment, incorporating oncologists from a wide range of specialties into each patient’s course of treatment. In addition to medical oncologists, the cancer care team may include thoracic surgeons, radiation oncologists and pulmonologists. These physicians work together closely to provide you with all the care and resources you need throughout the course of treatment. You may also benefit from a wide range of support services at IMP, including nutrition, palliative care and social work services. Many patients are able to see all of their specialists in one visit.

The team at IMP develops a treatment plan tailored to your specific diagnosis and needs. For many patients, a multimodal approach works best. Multimodal therapy involves some combination of surgery, radiation therapy and chemotherapy, and also may include one or more experimental therapies accessed through clinical trials. Treatment decisions vary depending on the tumor’s size and location, as well as your age and general health.

Surgery aiming to remove all visible mesothelioma tumors often extends the life expectancy of early-stage patients who are healthy enough for aggressive treatments. Cancer experts at IMP have pioneered a technique that combines surgery with a heated chemotherapy bath, which is delivered directly to the chest cavity after surgery. Heating the chemotherapy drugs improves the effectiveness of therapy, killing more of the cancer cells unavoidably left behind after surgery.

Surgery and other procedures that require you to be admitted to the hospital are offered at Brigham and Women’s Hospital. The Dana-Farber/Brigham and Women’s Cancer Center team at Brigham and Women’s provides post-surgical care and radiation therapy. Chemotherapy and other procedures that don’t require a hospital stay are offered at Dana-Farber’s Yawkey Center for Cancer Care. Housing for you and your family during treatment is provided by Thornton and Naumes House, located across the street from Brigham and Women’s.

Research Program

Research endeavors at the Dana-Farber Cancer Institute convert laboratory findings into noteworthy improvements in cancer education, prevention, diagnosis and treatment. What most distinguishes Dana-Farber’s research is the extent of its researchers’ collaboration. Resources are shared among the DF/HCC, which includes Dana-Farber, Brigham and Women’s, and several other hospitals and learning facilities. These institutions pool resources and advanced technology to improve cancer prevention, test experimental treatments and perform clinical and basic research.

As a principal teaching affiliate of Harvard medical School, Dana-Farber’s 19 core research facilities offer countless improvements in research, training and outreach opportunities for students, fellows and scientists alike. A large series of collaborative programs are organized based upon the study of specific diseases or research disciplines.

Medical oncologists, such as mesothelioma specialist Dr. Pasi A. Jänne, are breaking ground in the study of genetic factors that cause cancers to grow and spread. Jänne performs innovative laboratory studies at Dana-Farber/Brigham and Women’s Cancer Center to help scientists better understand mutated epidermal growth factor receptors (EGFR). Jänne believes that investigating ways to inhibit these receptors can prevent cancerous cells from resisting therapy. The research also may lead to more effective treatments for malignant mesothelioma and lung cancer.

Clinical Trials for Mesothelioma and Lung Cancer

Dana-Farber boasts one of the largest cancer clinical trials programs in the nation. These studies help to improve the quality of patient care by testing new approaches to therapy and different treatment combinations.

Several clinical trials at Dana-Farber are now recruiting patients, including:

Glutaminase Inhibitor CB-839

This two-part phase I trial will explore CB-839, an experimental drug that killed or slowed the growth of several types of cancer cells in preclinical studies. It works by depriving cancer cells of glutamine, an amino acid that drives the growth of many tumor cells, including mesothelioma. The first part of the study will help determine the best dose of CB-839 in patients with advanced tumors. The second part will evaluate the drug’s safety and effectiveness when combined with paclitaxel.

Trametinib and Navitoclax

This phase I and II trial will explore the best dose and potential side effects of trametinib and navitoclax in patients with advanced lung cancer and various other cancer types. Researchers suspect these experimental drugs may stop tumor cell growth by blocking some of the enzymes that cells need to grow.

Completed Clinical Trials

This phase I and II trial will explore the best dose and potential side effects of trametinib and navitoclax in patients with advanced lung cancer and various other cancer types. Researchers suspect these experimental drugs may stop tumor cell growth by blocking some of the enzymes that cells need to grow.

Additional Resources

  1. Dana-Farber Cancer Institute. (n.d.). How We Treat Mesothelioma. Retrieved from http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Mesothelioma/How-We-Treat-Mesothelioma.aspx
  2. Dana-Farber Cancer Institute. (n.d.). History of Dana-Farber Cancer Institute. Retreived from http://www.dana-farber.org/About-Us/History-and-Milestones.aspx
  3. The Jimmy Fund. (n.d.). Curing Cancer Bench to Bedside. Retrieved from http://www.jimmyfund.org/curing-cancer/bench-to-bedside/
  4. National Cancer Institute. (2015, January 7). Dana-Farber/Harvard Cancer Center. Retrieved from http://www.cancer.gov/research/nci-role/cancer-centers/find/dfharvard
  5. Brigham and Women's Hospital. (2015, July 20). The History of Brigham and Women's Hospital. Retrieved from http://www.brighamandwomens.org/About_BWH/about_us.aspx
  6. Brigham and Women's Hospital. (2014, October 23). Mesothelioma Overview. Retrieved from http://www.brighamandwomens.org/Departments_and_Services/surgery/services/thoracicsurgery/services/mesothelioma/default.aspx
  7. Brigham and Women's Hospital. (2015, April 15). About Research at BWH. Retrieved from http://www.brighamandwomens.org/Research/About/default.aspx
  8. U.S. News and World Report. (n.d.). Brigham and Women's Hospital. Retrieved from http://health.usnews.com/best-hospitals/brigham-and-women%27s-hospital-6140215
  9. U.S. National Institutes of Health. (2015, August 13). Study of the Glutaminase Inhibitor CB-839 in Solid Tumors. Retrieved from https://clinicaltrials.gov/ct2/show/NCT02071862
  10. U.S. National Institutes of Health. (2015, August 13). Trametinib and Navitoclax in Treating Patients with Advanced or Metastatic Solid Tumors. Retrieved from https://clinicaltrials.gov/ct2/show/NCT02079740
  11. Calithera Biosciences. (n.d.). CB-839 Has the Potential to Be an Important New Therapeutic Agent with a Novel Mechanism of Action for the Treatment of a Broad Range of Cancers. Retrieved from http://www.calithera.com/programs/cb-839/

Share Our Page

View our resources for patients and families

Get Help Today
Click for Free Patient Resources